Evidence map›Paper›PMID 42596896›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Whooping cough hospitalisations among patients with chronic conditions: a retrospective analysis of incidence and costs, France, 2008 to 2020.

Juan C Vargas-Zambrano, Mickael Arnaud, Ana Antunes, Khalil Karzazi, Johanna Despres, Regis Verdier, Florence Boisnard, Jerome Jund, Cecile Janssen, Didier Pinquier and 1 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Juan C Vargas-ZambranoGlobal Medical, Vaccines, Sanofi, Lyon, France.
Mickael ArnaudReal World Solutions, IQVIA, Bordeaux, France.
Ana AntunesReal World Solutions, IQVIA, Lisbon, Portugal.
Khalil KarzaziReal World Solutions, IQVIA, Paris, France.
Johanna DespresReal World Solutions, IQVIA, Paris, France.
Regis VerdierFrance Medical, Vaccines, Sanofi, Lyon, France.
Florence BoisnardGlobal Medical, Vaccines, Sanofi, Lyon, France.
Jerome JundService d'information et d'Evaluation médicale, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
Cecile JanssenService d'Infectiologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.
Didier PinquierService de Pédiatrie Néonatale et Réanimation, University of Rouen Normandy, CHU Rouen, Hôpital Charles Nicolle, Rouen, France.
Denis MacinaGlobal Medical, Vaccines, Sanofi, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDIn European countries, including France, the incidence and costs of whooping cough in people with chronic conditions remains understudied.AIMWe aimed to estimate cumulative incidence and costs of whooping cough hospitalisations in children, adolescents and adults with chronic conditions in France.METHODSWe extracted data from patients hospitalised with whooping cough with or without underlying chronic conditions, asthma, chronic obstructive pulmonary disease (COPD), diabetes and immunocompromising conditions between 2008 and 2020 using the Système National des Données de Santé (SNDS).RESULTSAmong the 10,893 patients hospitalised with whooping cough in 2008-2020, asthma and/or COPD were the most common chronic conditions. Of the 7,212 children and adolescents hospitalised, 1,263 (17.5%) had asthma and 68 (0.9%) had an immunocompromising condition. Of the 3,681 adults, 2,297 (62.4%) had asthma and/or COPD, 594 (16.1%) had an immunocompromising condition and 454 (12.3%) had diabetes. In children and adolescents, the highest cumulative incidence ratio (CIR) was among patients with an immunocompromising condition (adjusted CIR = 3.6; 95% confidence interval (CI): 2.8-4.6) whereas in adults, patients with asthma and/or COPD had the highest adjusted CIR (18.6; 95% CI: 17.4-19.9). Median hospitalisation costs were the highest for patients with an immunocompromising condition (EUR 4,401). No significant changes in healthcare resource utilisation were observed before and after whooping cough hospitalisation in adults.CONCLUSIONChronic conditions are associated with higher cumulative incidence of whooping cough-related hospitalisation in France. This highlights the importance of reducing whooping cough circulation, through strengthening vaccination programmes, particularly for those with chronic conditions.

Indexed as

Health Care CostsHospitalizationWhooping CoughAdolescentAdultAgedAsthmaChildChild, PreschoolChronic DiseaseFemaleFranceHumansIncidenceInfantMaleAsthmachronic conditionsCOPDHospitalisationimmunocompromising conditionsPertussiswhooping cough

Identifiers

PMID42596896
PMCPMC13476727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.